More studies needed after cabazitaxel shows promise in dedifferentiated liposarcoma
In a nonrandomized phase 2 clinical trial, patients with advanced dedifferentiated liposarcoma (DDLPS) treated with cabazitaxel had a median progression-free survival of 6.5 months, exceeding expectations and warranting investigation in phase 3 trials.
A total of 38 patients with advanced histologically proven DDLPS with evidence of disease progression within the past 6 months who had received ≤1 line of prior chemotherapy were treated with cabazitaxel (25 mg/m2 IV infusion) over 1 hour every 21 days until intolerance, progression, or withdrawal of consent.
At 12 weeks, progression-free survival (PFS) was 55%, achieving the primary study end point. At a median of 21.6 months follow-up, median PFS was 6 months and median overall survival was 21 months.
The overall response rate was 8%. One patient and 2 patients had clinical and partial responses, respectively, and stable disease was noted in 60.5% of patients (n = 23). Disease was achieved in 68% of patients (n = 26).
ReferenceSanfilippo R, Hayward RL, Musoro J, et al. Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). JAMA Oncol. Published online August 18, 2022. doi:10.1001/jamaoncol.2022.3218
